Publications by authors named "Fenting Lei"
Biomimetic nanoplatform treats myocardial ischemia/reperfusion injury by synergistically promoting angiogenesis and inhibiting inflammation.
Colloids Surf B Biointerfaces
November 2024
After myocardial ischemia/reperfusion injury (MI/RI), endothelial cell injury causes impaired angiogenesis and obstruction of microcirculation, resulting in an inflammatory outburst that exacerbates the damage. Therefore, synergistic blood vessel repair and inflammation inhibition are effective therapeutic strategies. In this study, we developed a platelet membrane (PM)-encapsulated baicalin nanocrystalline (BA NC) nanoplatform with a high drug load, BA NC@PM, which co-target to endothelial cells and macrophages through the transmembrane proteins of the PM to promote angiogenesis and achieve anti-inflammatory effects.
View Article and Find Full Text PDFArticle Synopsis
- Oral nano-delivery systems struggle to deliver drugs effectively to the colon for treating inflammatory bowel disease (IBD), highlighting the need for improved methods that can respond to the specific microenvironment of the gut.
- This study successfully developed a pH-responsive sodium alginate hydrogel-coated nanoemulsion (CUR/EMO NE@SA) that co-delivers curcumin and emodin, offering controlled drug release and targeted action against macrophages in the inflamed colon.
- The CUR/EMO NE@SA formulation showed significant reductions in pro-inflammatory markers and enhanced mucosal repair, suggesting a new therapeutic approach for IBD by combining anti-inflammatory and mucosal restoration effects in a targeted manner.
Dexamethasone sodium phosphate (Dex) is widely used in the clinic for the treatment of rheumatoid arthritis. However, it circulates in the blood for a short time and it is linked to a high risk of severe side effects caused by repeated dosing. Here, we encapsulated Dex onto zeolitic imidazolate framework-8 (ZIF-8) to prepare metal-organic framework nanoparticles with high drug loading efficiency.
View Article and Find Full Text PDFRheumatoid arthritis (RA) is a chronic systemic autoimmune disease, which is characterized by synovial inflammation and autoimmunity. The main cause of the disease is the imbalance of the proportion of pro-inflammatory macrophages (M1-type) and anti-inflammatory macrophages (M2-type) in the synovial tissues of the joint. To restore this balance, in our study, the interleukin-10 encoding anti-inflammatory cytokines (IL-10 pDNA) and chemotherapeutic drug dexamethasone sodium phosphate (DSP) were co-loaded into human serum albumin (HSA) preparing pDNA/DSP-NPs to actively target macrophages in synovium tissue to promote M1-M2 polarization.
View Article and Find Full Text PDF